Silexion Therapeutics (SLXNW) Stock Analysis

What Silexion Therapeutics does

Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer. Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

Key metrics

ETFs linked to SLXNW

Broad-market and Healthcare sector ETFs an investor holding Silexion Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SLXNW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Silexion Therapeutics?

Silexion Therapeutics trades under the ticker SLXNW on NASDAQ.

Which exchange is SLXNW listed on?

SLXNW is listed on NASDAQ.

What sector does Silexion Therapeutics operate in?

Silexion Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SLXNW in a portfolio?

PortView shows SLXNW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.